In this issue:
PREVANZ: Vitamin D & MS onset
EBV & risk of MS
Immune-mediated colitis with ocrelizumab
Dimethyl fumarate for PPMS
AHSCT vs. fingolimod, natalizumab or ocrelizumab for RRMS
KFLC index & OCBs for MS diagnosis
Optic nerve involvement in MS diagnosis
Standard vs. extended interval dosing of ocrelizumab
Publication bias in MS trials
Siblings, EBV & risk of MS
Please login below to download this issue (PDF)